posit progress evid
maintain market outperform rate
rais price target follow friday releas
result new price target base previous
ep estim vs prior ep updat multipl
incorpor diminish risk concern compani suppli issu although
note uncertainti remain progress still necessari
second quarter result solid beat consensu sale
knee hip spine cmf second quarter ep came
street estim
full-year sale guidanc slightli adjust lower call sale
bln y/i flattish slightli cc bp
posit fx impact prior revenu guidanc call y/i
growth includ bp fx indic modest uptick cc
expect previous announc ep guidanc reiter rang
expect similarli remain stabl
call ceo bryan hanson reiter continu focu
previous state key prioriti right ship near term enhanc
cultur drive on-going remedi process suppli recoveri
effort scale new product launch risk remain
compani work recoveri effort hanson express cautiou
optim concern progress zimmer made toward achiev short-
term goal manag emphas import first establish steadi
state suppli coupl new product option re-energ
sale forc drive potenti revenu acceler
multipl product launch continu perform well sever
pipelin expect end year releas thu far
compani introduc new addit persona famili partial
knee tibia system fulli launch later
compani also plan number new product launch toward
end includ limit launch persona revis system
total knee applic rosa robot platform
total revenu bln y/i cc versu street
bln estim bln guidanc bln high
end total price continu recent trend volum
fx benefit provid respect adjust ep vs
last year consensu estim
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
america sale bln y/i cc emea revenu
mln y/i cc asia pacif sale mln y/i cc
within larg joint segment knee hip came street expect
estim knee sale mln higher consensu
y/i cc growth volum benefit fx partial
off-set price total hip sale mln beat consensu
y/i cc posit volum growth fx
price
turn divis set post growth cc slightli
consensu spine cmf outperform consensu moder growth
cc zimmer dental divis continu declin cc
manag rais guidanc bln previous bln
expect de-lever primari use cash current compani
maintain leverag ratio slightli goal reduc threshold
expect could achiev
concern remedi obstacl manag addit updat
regard fda observ warsaw north campu facil
previous announc compani submit respons fda facil
current manufactur full rang product
stock remain inexpens versu peer vs peer ep
still believ merger yield mani advantag longer term
manag believ return industry-lik mid-singl digit sale growth
least equival market rate double-digit ep growth potenti remain
realist may take littl time get
manag updat full-year guidanc anticip revenu bln
y/i flattish slightli cc bp posit fx impact adjust
y/i growth bp fx compani reiter ep
rais free cash flow bln previous bln
bp midpoint fx bp improvementrevenu growth cc flat slightli zimmer biomet hold inc
figur highlight actual vs jmp estim rang revenu metric along
select commentari
 edeltacommentsreconstruct cc america cc emea cc apac cc driven persona person knee recent addit partial knee tibia system full launch end limit launch plan eoy includ persona revis tka rosa platform annual cc america cc emea cc apac cc addit inform avail warsaw north campu reimspect facil continu manufactur full rang product timeannu bpstotal larg cc pressur littl larg joint term suppli recoveri time capit benefit realiz cc dental market remain tough make chang segment senior manag annual bpsspine cc goal limit launch spine applic rosa robot potenti follow rosa knee applic annual ccannual bpstotal blnannual bpsgross bpsdown bp y/i due increment manufactur inventori cost price declin slight benefit mix bpsup bp bpsoper bpstax bpsnet zimmer biomet hold inc
largest pure-play public musculoskelet compani long histori stand-alone med-tech firm zimmer spun
manag remain commit orthoped root reconstruct implant still garner major total
revenu today focu bless curs larg depend upon fundament underli hip knee
market biomet acquisit complet reinforc zimmer orthoped focu creat much larger presenc key
highli lever recon market focu challeng depend underli fundament volum rebound
core orthoped arena may occur price like remain headwind across sector new product may perform well
anticip signific ou exposur primarili europ asia may subject headwind tailwind aris
geographi new market entrant may introduc novel devic procedur busi model could significantli chang market
dynam time make difficult compet sizabl larg tradit product portfolio
research analyst prepar report does/do herebi certifi view present report accord my/our
person view secur issuer discuss report mandat sec regul ac part my/our compens
directli indirectli relat specif view recommend express herein certif made
oblig set forth sec regul ac person entiti may use purpos certif made
base my/our analysi date report public i/w assum oblig updat certif reflect fact
circumst event may subsequ come my/our attent sign david turkali daniel stauder
